Mary Ann Karam

727 citations

28 papers · 534 indexed · h-index 12

Co-authors: Mohamad A. Hussein Rachid Baz Gordan Srkalović Beth Faiman Steven Andrèsen Janice Reed Megan Kelly Jerome B. Zeldis
Topics: Multiple Myeloma Research and Treatments (22 papers)Protein Degradation and Inhibitors (9 papers)Cancer Treatment and Pharmacology (8 papers)
Cited by: Hematology Internal Medicine Genetics
Journals: Journal of Clinical Oncology Blood Mayo Clinic Proceedings
Partner nations: United States Egypt Uganda

In The Last Decade

Mary Ann Karam

27 papers receiving 525 citations

Peers

Countries citing papers authored by Mary Ann Karam

Since Specialization

Citations

This map shows the geographic impact of Mary Ann Karam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ann Karam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ann Karam more than expected).

Fields of papers citing papers by Mary Ann Karam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Ann Karam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ann Karam. The network helps show where Mary Ann Karam may publish in the future.

Co-authorship network of co-authors of Mary Ann Karam

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ann Karam. A scholar is included among the top collaborators of Mary Ann Karam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ann Karam. Mary Ann Karam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients 2019 ·Blood ·Fahrettin Covut,(unknown),Christy Samaras,Faiz Anwer,Alex Garcia,Dana E. Angelini,Beth Faiman,Janice Reed,Mary Ann Karam,(unknown),(unknown),(unknown),(unknown),Jason Valent,Jack Khouri	1
2	Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis 2018 ·Blood ·Sarah S. Lee,(unknown),Bhumika Patel,(unknown),(unknown),(unknown),Mary Ann Karam,Janice Reed,Beth Faiman,(unknown),(unknown),Christy Samaras,Jason Valent	6
3	Daratumumab proves safe and highly effective in AL amyloidosis 2018 ·British Journal of Haematology ·Jack Khouri,(unknown),Bicky Thapa,Frederic J. Reu,Naresh Bumma,Christy Samaras,Hien Liu,Mary Ann Karam,Janice Reed,(unknown),Beth Faiman,(unknown),Jeffrey A. Zonder,Jason Valent	39
4	A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. 2015 ·Journal of Clinical Oncology ·Frederic J. Reu,Dale Grabowski,Reda Z. Mahfouz,Hillard M. Lazarus,Robert M. Dean,Beth Faiman,Janice Reed,Mary Ann Karam,(unknown),(unknown),Matt Kalaycio,Jason Valent,Christy Samaras,Ronald Sobecks,(unknown),(unknown),Hien Liu,Yogen Saunthararajah,Yap Ching Chew,Mitchell R. Smith	2
5	Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy 2014 ·Blood ·Mayur Narkhede,Jason Valent,Chad Cummings,(unknown),Debbie Hastings,Beth Faiman,(unknown),Janice Reed,Mary Ann Karam,Matt Kalaycio,Brian J. Bolwell,Mitchell R. Smith,Hien K. Duong,Christy Samaras,Frederic J. Reu	2
6	Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma 2010 ·Blood ·Aleksandr Lazaryan,Rachid Baz,Mohamad A. Hussein,Paul Elson,Beth Faiman,(unknown),Mary Ann Karam,Janice Reed,(unknown),(unknown),Gordan Srkalović,Steven Andrèsen,Matt Kalaycio,John Sweetenham,Ronald Sobecks,Robert M. Dean,Robert Knight,Jerome B. Zeldis,Frederic J. Reu	1
7	Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma 2007 ·Leukemia & lymphoma ·Rachid Baz,Suzanne Fanning,Lori Kunkel,Sameh Gaballa,Mary Ann Karam,Janice Reed,Megan Kelly,Mohamad A. Hussein	11
8	An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications 2007 ·British Journal of Urology ·Toni K. Choueiri,Rachid Baz,(unknown),Mohamad Khasawneh,Mary Ann Karam,Megan Kelly,Mohamad A. Hussein	19
9	Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma 2006 ·Mayo Clinic Proceedings ·Mohamad A. Hussein,Rachid Baz,Gordan Srkalović,(unknown),(unknown),Eric D. Hsi,Steven Andrèsen,Mary Ann Karam,Janice Reed,Beth Faiman,Megan Kelly,Esteban Walker	84
10	Efficacy and Safety Results with the Combination Therapy of Arsenic Trioxide, Dexamethasone, and Ascorbic Acid in Multiple Myeloma Patients: A Phase 2 Trial 2006 ·Medical Oncology ·Rony M. Abou-Jawde,Janice Reed,Megan Kelly,Esteban Walker,Steven Andrèsen,Rachid Baz,Mary Ann Karam,Mohamad A. Hussein	33
11	The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. 2006 ·PubMed ·Rony M. Abou-Jawde,Rachid Baz,Esteban Walker,Toni K. Choueiri,Mary Ann Karam,Janice Reed,Beth Faiman,Mohamad A. Hussein	24
12	The Role of Aspirin in the Prevention of Thrombotic Complications of Thalidomide and Anthracycline-Based Chemotherapy for Multiple Myeloma 2005 ·Mayo Clinic Proceedings ·Rachid Baz,Liang Li,Kandice Kottke‐Marchant,Gordan Srkalović,(unknown),(unknown),Mary Ann Karam,Beth Faiman,Rony Abou Jawde,Steven Andrèsen,Jerome B. Zeldis,Mohamad A. Hussein	168
13	Doxil, Vincritine, Reduced Frequency Dexamethasone in Combination with Thalidomide (DVd-T) Is Associated with Higher Overall and Progression Free Survival as Compared to DVd in Patients with Multiple Myeloma (MM). 2005 ·Blood ·Khaldoun Almhanna,(unknown),Rachid Baz,Mary Ann Karam,Beth Faiman,Janice Reed,Mohamad A. Hussein	4
14	Full Dose Vincristine (V) Negatively Impacts Progression Free Survival in Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Treated with Pegylated Doxorubicin, Vincristine, Reduced-Dose Dexamethasone, and Thalidomide (DVd-T). 2005 ·Blood ·(unknown),Esteban Walker,Khaldoun Almhanna,Steve Andresen,Janice Reed,Mary Ann Karam,(unknown),Megan Kelly,(unknown),(unknown),M. A. Hussein	1
15	Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients. 2004 ·Blood ·Mohamad A. Hussein,Mary Ann Karam,C. Brand,Greg Pearce,Janice Reed,(unknown),(unknown),Gordan Srkalović,Marta Olesnyckyj,Robert Knight,(unknown),Jerome B. Zeldis	8
16	A Phase II Trial of Doxil, Vincristine and Reduced Schedule Dexamethasone (DVd) for Patients with Relapsed or Refractory Multiple Myeloma. 2004 ·Blood ·(unknown),Mary Ann Karam,(unknown),Steven Andrèsen,Alan Lichtin,(unknown),Mohamad A. Hussein	2
17	Skeletal Trauma Preceding the Development of Plasma Cell Dyscrasia: Eight Case Reports and Review of the Literature 2003 ·Medical Oncology ·M. A. Hussein,(unknown),Lisa Rybicki,Mary Ann Karam	8
18	Etanercept Therapy in Patients with Advanced Primary Amyloidosis 2003 ·Medical Oncology ·M. A. Hussein,(unknown),Lisa Rybicki,(unknown),Blain Murphy,Mary Ann Karam	15
19	Use of Melphalan, Thalidomide, and Dexamethasone in Treatment of Refractory and Relapsed Multiple Myeloma 2002 ·Medical Oncology ·Gordan Srkalović,Paul Elson,(unknown),Mary Ann Karam,Mohamad A. Hussein	38
20	Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial. 1998 ·Sexually Transmitted Infections ·Elly Katabira,Nelson K. Sewankambo,Roy D. Mugerwa,E M Belsey,(unknown),(unknown),Peter Kataaha,Mary Ann Karam,M Youle,Jos Perriëns,J. M. A. Lange	14

About Mary Ann Karam

Mary Ann Karam is a scholar working on Hematology, Oncology and Genetics, having authored 28 papers that have together received 534 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (9 papers) and Cancer Treatment and Pharmacology (8 papers). The work is most often cited by research in Hematology (360 citations), Internal Medicine (63 citations) and Genetics (113 citations). Mary Ann Karam has collaborated with scholars based in United States, Egypt and Uganda. Frequent co-authors include Mohamad A. Hussein, Rachid Baz, Gordan Srkalović, Beth Faiman, Steven Andrèsen, Janice Reed, Megan Kelly, Jerome B. Zeldis, Rony Abou Jawde and Esteban Walker. Their work appears in journals such as Journal of Clinical Oncology, Blood and Mayo Clinic Proceedings.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact